> [...] different clinical protocols could rapidly obsolete the 9902b trial protocol and further improve upon 9901/9902a efficacy.
No kidding. It is not hard to imagine, that upon Provenge approval, physicians would prefer the Avastin/Provenge combination rather than one with taxotere chemotherapy, due to toxicity concerns.
That said, would Genentech necessarily be the driver of any associated Phase 3 clinical trial, or would that depend upon DNA being involved financially in a partnership agreement? I assume combination trials are unnecessary where reimbursement is not an issue.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.